Brief: Entrada Therapeutics Doses First Participant In Phase 1 Trial Of Entr-601-44 In Treating Duchenne Muscular Dystrophy
21/09/2023 12:35
Sept 21 (Reuters) - Entrada Therapeutics Inc TRDA.O :
* ENTRADA THERAPEUTICS ANNOUNCES FIRST PARTICIPANT DOSED IN
ITS
PHASE 1 CLINICAL TRIAL OF ENTR-601-44 FOR THE POTENTIAL
TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY
* ENTRADA THERAPEUTICS INC: EXPECT TO REPORT DATA FROM PHASE
1
TRIAL IN SECOND HALF OF 2024
* ENTRADA THERAPEUTICS INC - DATA ANTICIPATED IN SECOND HALF
OF
2024
Source text for Eikon: ID:nGNX1zGfBK
Further company coverage: TRDA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Entrada Therapeutics
See all newsBrief: Entrada Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Entrada Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Entrada Therapeutics Q2 Collaboration Revenue USD 898 Thousand
Entrada Therapeutics Q2 net loss narrows on lower costs
Entrada Therapeutics Inc expected to post a loss of $1.05 a share - Earnings Preview